Renascience

News

2024.01.19 news
Notice of Publication of Article Related to the Development of RS5614, a PAI-1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer
2024.01.03 news
Notice of Publication of Article on Results of Late Phase II Study of Novel Coronavirus Lung Injury
2023.11.13 news
Notice of Publication of Article on Cutaneous Angiosarcoma Phase II Study Protocol
2023.09.29 news
Notice of Publication of Article Related to the Development of RS5614, a PAI-1 Inhibitor, for the Treatment of Malignant Melanoma
2023.09.01 news
Notice of Publication of Article on Our Pipeline in Global Bio Investment Magazine
2023.08.16 news
Nihon Keizai Shimbun Published the Article on the Results of Phase II Malignant Melanoma Study

IR News

2024.03.18Others
Notice of Publication of Article Related to the C o mpany s Software as a Medical Device in Nature(106KB)
2024.03.14Timely Disclosure
Notice of Conclusion of Collaboration Agreement with Nipro Corporation(143KB)
2024.03.07Timely Disclosure
Participation in the Program on Open Innovation Platform with Enterprises, Research Institute and Academia (OPERA) of Japan Science and Technology Agency (JST)(296KB)
2024.02.22Timely Disclosure
Final Results of Phase II Investigator-Initiated Clinical Trial of PAI-1 inhibitor RS5614 for Malignant Melanoma Refractory to Nivolumab(227KB)
2024.02.06Timely Disclosure
Completion of Treatment of Final Patient in Phase II Investigator-Initiated Clinical Trial of RS8001 (pyridoxamine) for Premenstrual Syndrome with Psychiatric Symptoms/Premenstrual Dysphoric Disorder(130KB)

About Our Company　>>

We would like to give you a brief introduction to Renascience's corporate activities.

Our Strengths

We introduce our business model.

R&D Pipelines

You can view the progress of each project here.

Management

We are pleased to introduce our officers.

FAQ

You can read about frequently asked questions.